

# David W Cescon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2912210/publications.pdf>

Version: 2024-02-01

96  
papers

8,480  
citations

101543

36  
h-index

48315

88  
g-index

98  
all docs

98  
docs citations

98  
times ranked

13418  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mutations in Noncoding <i>Cis</i> -Regulatory Elements Reveal Cancer Driver Cistromes in Luminal Breast Cancer. <i>Molecular Cancer Research</i> , 2022, 20, 102-113.	3.4	3
2	Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer Therapies. <i>Advanced Healthcare Materials</i> , 2022, 11, e2101085.	7.6	48
3	Novel classes of immunotherapy for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 15-29.	2.5	8
4	Breast cancer immune microenvironment: from pre-clinical models to clinical therapies. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 257-267.	2.5	10
5	Development of novel agents for the treatment of early estrogen receptor positive breast cancer. <i>Breast</i> , 2022, 62, S34-S42.	2.2	8
6	Radiotherapy and radiosensitization in breast cancer: Molecular targets and clinical applications. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 169, 103566.	4.4	8
7	Biomimetic hydrogel supports initiation and growth of patient-derived breast tumor organoids. <i>Nature Communications</i> , 2022, 13, 1466.	12.8	48
8	Current Treatment and Future Trends of Immunotherapy in Breast Cancer. <i>Current Cancer Drug Targets</i> , 2022, 22, 667-677.	1.6	5
9	Transcriptomic Determinants of Response to Pembrolizumab Monotherapy across Solid Tumor Types. <i>Clinical Cancer Research</i> , 2022, 28, 1680-1689.	7.0	32
10	No evidence of disease versus residual disease in long-term responders to first-line HER2-targeted therapy for metastatic breast cancer. <i>British Journal of Cancer</i> , 2022, 126, 881-888.	6.4	5
11	164O Health-related quality of life (HRQoL) with pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (pbo) + chemo as 1L treatment for advanced triple-negative breast cancer (TNBC): Results from KEYNOTE-355. <i>Annals of Oncology</i> , 2022, 33, S197-S198.	1.2	1
12	PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. <i>Nature Chemical Biology</i> , 2022, 18, 821-830.	8.0	43
13	Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?. <i>Journal of Clinical Oncology</i> , 2022, 40, 2395-2397.	1.6	1
14	Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies. <i>Nature Communications</i> , 2022, 13, .	12.8	43
15	On the Road to Precision: Understanding the Biology Driving Genomic Assays. <i>Journal of Clinical Oncology</i> , 2021, 39, 100-102.	1.6	5
16	Mevalonate Pathway Inhibition Slows Breast Cancer Metastasis via Reduced <i>N</i> -glycosylation Abundance and Branching. <i>Cancer Research</i> , 2021, 81, 2625-2635.	0.9	24
17	Pembrolizumab monotherapy in metastatic triple-negative breast cancer. <i>Lancet Oncology</i> , The, 2021, 22, 415-417.	10.7	3
18	Anticancer effects of radiation therapy combined with Polo-Like Kinase 4 (PLK4) inhibitor CFI-400945 in triple negative breast cancer. <i>Breast</i> , 2021, 58, 6-9.	2.2	15

#	ARTICLE	IF	CITATIONS
19	LBA16 KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab + chemotherapy vs placebo + chemotherapy for metastatic TNBC. <i>Annals of Oncology</i> , 2021, 32, S1289-S1290.	1.2	33
20	Accelerating drug access from advanced to early breast cancer. <i>Current Opinion in Oncology</i> , 2021, Publish Ahead of Print, 538-546.	2.4	0
21	531P Binimetinib and encorafenib for the treatment of advanced solid tumors with non-V600E BRAF mutations (mts): Preliminary results of the investigator initiated phase II BEAVER trial. <i>Annals of Oncology</i> , 2021, 32, S596.	1.2	1
22	Network Meta-analysis Comparing Efficacy, Safety and Tolerability of Anti-PD-1/PD-L1 Antibodies in Solid Cancers. <i>Journal of Cancer</i> , 2021, 12, 4372-4378.	2.5	9
23	PARP inhibitor sensitivity in BRCA-related metastatic breast cancer: an OlympiAD later. <i>Annals of Oncology</i> , 2021, 32, 1460-1462.	1.2	4
24	Assessing therapy response in patient-derived xenografts. <i>Science Translational Medicine</i> , 2021, 13, eabf4969.	12.4	5
25	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397.	2.8	11
26	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. <i>Lancet, The</i> , 2020, 396, 1817-1828.	13.7	992
27	356TiP A phase II/III, open-label, randomized trial of pembrolizumab + olaparib vs. pembrolizumab + chemotherapy after induction with pembrolizumab + chemotherapy in locally recurrent inoperable or metastatic triple-negative breast cancer: KEYLYNK-009. <i>Annals of Oncology</i> , 2020, 31, S392.	1.2	1
28	Biomarkers of outcome to weekly paclitaxel in epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 2020, 159, 539-545.	1.4	4
29	GLUT1 inhibition blocks growth of RB1-positive triple negative breast cancer. <i>Nature Communications</i> , 2020, 11, 4205.	12.8	130
30	19O A phase Ib trial of CFI-402257 in combination with weekly paclitaxel in patients with advanced HER2-negative (HER2-) breast cancer (aBC). <i>Annals of Oncology</i> , 2020, 31, S7.	1.2	2
31	43O Phase III KEYNOTE-355 study of pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC): Results for patients (Pts) enrolled in Asia. <i>Annals of Oncology</i> , 2020, 31, S1257.	1.2	2
32	68TiP KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) + olaparib (ola) vs pembro + chemotherapy after induction with first-line (1L) pembro + chemo in patients (pts) with locally recurrent inoperable or metastatic TNBC. <i>Annals of Oncology</i> , 2020, 31, S1268.	1.2	2
33	Patterns of Recurrence and Predictors of Survival in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy, Surgery, and Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 676-685.	0.8	9
34	Association between BMI, vitamin D, and estrogen levels in postmenopausal women using adjuvant letrozole: a prospective study. <i>Npj Breast Cancer</i> , 2020, 6, 22.	5.2	7
35	Epigenetic Switchâ€œInduced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer. <i>Cancer Discovery</i> , 2020, 10, 1312-1329.	9.4	84
36	Circulating tumor DNA and liquid biopsy in oncology. <i>Nature Cancer</i> , 2020, 1, 276-290.	13.2	309

#	ARTICLE	IF	CITATIONS
37	Toronto Workshop on Late Recurrence in Estrogen Receptor-Positive Breast Cancer: Part 2: Approaches to Predict and Identify Late Recurrence, Research Directions. JNCI Cancer Spectrum, 2019, 3, pkz049.	2.9	11
38	Benchmarking to the Gold Standard: Hyaluronanâ€Oxime Hydrogels Recapitulate Xenograft Models with In Vitro Breast Cancer Spheroid Culture. Advanced Materials, 2019, 31, e1901166.	21.0	51
39	Safety and tolerability of CFI-400945, a first-in-class, selective PLK4 inhibitor in advanced solid tumours: a phase 1 dose-escalation trial. British Journal of Cancer, 2019, 121, 318-324.	6.4	35
40	Tyrosine Threonine Kinase Inhibition Eliminates Lung Cancers by Augmenting Apoptosis and Polyploidy. Molecular Cancer Therapeutics, 2019, 18, 1775-1786.	4.1	21
41	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer. Npj Breast Cancer, 2019, 5, 34.	5.2	55
42	Toronto Workshop on Late Recurrence in Estrogen Receptorâ€Positive Breast Cancer: Part 1: Late Recurrence: Current Understanding, Clinical Considerations. JNCI Cancer Spectrum, 2019, 3, pkz050.	2.9	15
43	If we build it they will come: targeting the immune response to breast cancer. Npj Breast Cancer, 2019, 5, 37.	5.2	132
44	A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast, 2019, 48, 17-23.	2.2	73
45	MicroSPECT/CT Imaging of Cell-Line and Patient-Derived EGFR-Positive Tumor Xenografts in Mice with Panitumumab Fab Modified with Hexahistidine Peptides To Enable Labeling with <sup>99m</sup> Tc(I) Tricarbonyl Complex. Molecular Pharmaceutics, 2019, 16, 3559-3568.	4.6	10
46	Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts. Cancer Research, 2019, 79, 4539-4550.	0.9	34
47	AhR controls redox homeostasis and shapes the tumor microenvironment in BRCA1-associated breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 3604-3613.	7.1	96
48	Reactive oxygen species modulate macrophage immunosuppressive phenotype through the up-regulation of PD-L1. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 4326-4335.	7.1	137
49	Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study. Annals of Oncology, 2019, 30, 405-411.	1.2	419
50	Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study. Annals of Oncology, 2019, 30, 397-404.	1.2	538
51	KEYNOTE-756: A randomized, double-blind, phase III study of pembrolizumab or placebo with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage, ER+/HER2â€breast cancer. Annals of Oncology, 2019, 30, ix7-ix8.	1.2	1
52	Polo-like kinase 4 inhibition produces polyploidy and apoptotic death of lung cancers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 1913-1918.	7.1	64
53	Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1570-E1577.	7.1	62
54	Influence of control group therapy on the benefit from dose-dense chemotherapy in early breast cancer: a systemic review and meta-analysis. Breast Cancer Research and Treatment, 2018, 169, 413-425.	2.5	14

#	ARTICLE	IF	CITATIONS
55	Pharmacology and in vivo efficacy of pyridine-pyrimidine amides that inhibit microtubule polymerization. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2018, 28, 934-941.	2.2	13
56	Toxicity of Extended Adjuvant Therapy With Aromatase Inhibitors in Early Breast Cancer: A Systematic Review and Meta-analysis. <i>Journal of the National Cancer Institute</i> , 2018, 110, 31-39.	6.3	129
57	Impact of multi-gene mutational profiling on clinical trial outcomes in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 159-168.	2.5	27
58	The Antiarrhythmic Drug, Dronedarone, Demonstrates Cytotoxic Effects in Breast Cancer Independent of Thyroid Hormone Receptor Alpha 1 (THR1±1) Antagonism. <i>Scientific Reports</i> , 2018, 8, 16562.	3.3	8
59	Gene Expression Analyses in Breast Cancer: Sample Matters. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky019.	2.9	0
60	MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis. <i>Cancer Cell</i> , 2018, 34, 579-595.e8.	16.8	94
61	Reply to Oegema et al.: CFI-400945 and Polo-like kinase 4 inhibition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E10810-E10811.	7.1	5
62	Evolution in sites of recurrence over time in breast cancer patients treated with adjuvant endocrine therapy. <i>Cancer Treatment Reviews</i> , 2018, 70, 138-143.	7.7	9
63	Targeting the cell cycle in breast cancer: towards the next phase. <i>Cell Cycle</i> , 2018, 17, 1871-1885.	2.6	108
64	Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials. <i>European Journal of Cancer</i> , 2017, 77, 40-47.	2.8	52
65	BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 Trial. <i>Clinical Cancer Research</i> , 2017, 23, 2460-2470.	7.0	8
66	Relationship between tumor infiltrating lymphocyte (TIL) levels and response to pembrolizumab (pembro) in metastatic triple-negative breast cancer (mTNBC): Results from KEYNOTE-086. <i>Annals of Oncology</i> , 2017, 28, v608.	1.2	117
67	DNA replication stress: a source of APOBEC3B expression in breast cancer. <i>Genome Biology</i> , 2016, 17, 202.	8.8	16
68	Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer. <i>Nature Genetics</i> , 2016, 48, 1260-1266.	21.4	75
69	Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2. <i>Cancer Cell</i> , 2016, 30, 337-348.	16.8	166
70	A phase I trial of ANG1/2-Tie2 inhibitor trebaninib (AMG386) and temsirolimus in advanced solid tumors (PJC008/NCI#9041). <i>Investigational New Drugs</i> , 2016, 34, 104-111.	2.6	17
71	Abstract CT066: First-in-human phase I trial of the oral PLK4 inhibitor CFI-400945 in patients with advanced solid tumors. <i>Cancer Research</i> , 2016, 76, CT066-CT066.	0.9	6
72	Glutathione and Thioredoxin Antioxidant Pathways Synergize to Drive Cancer Initiation and Progression. <i>Cancer Cell</i> , 2015, 27, 211-222.	16.8	748

#	ARTICLE	IF	CITATIONS
73	Breaking up Is Hard to Do: PI3K Isoforms on the Rebound. <i>Cancer Cell</i> , 2015, 27, 5-7.	16.8	14
74	<i>APOBEC3B</i> expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 2841-2846.	7.1	118
75	NRF2 Pathway Activation and Adjuvant Chemotherapy Benefit in Lung Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2015, 21, 2499-2505.	7.0	48
76	Estrogen controls the survival of BRCA1-deficient cells via a PI3K-NRF2-regulated pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 4472-4477.	7.1	100
77	Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent. <i>Cancer Cell</i> , 2014, 26, 163-176.	16.8	150
78	Extended Adjuvant Tamoxifen for Early Breast Cancer: A Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e88238.	2.5	51
79	Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. <i>Genes and Development</i> , 2013, 27, 1101-1114.	5.9	113
80	BRCA1 interacts with Nrf2 to regulate antioxidant signaling and cell survival. <i>Journal of Experimental Medicine</i> , 2013, 210, 1529-1544.	8.5	239
81	Association of <i>MDM2</i> and <i>p53</i> polymorphisms and gastroesophageal reflux disease with survival in esophageal adenocarcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2013, 28, 1482-1488.	2.8	12
82	Phase I trial of trebananib (AMG 386) plus temsirolimus (Tr + T) in patients (pts) with advanced solid tumors (PJC-008/NCI#9041).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2534-2534.	1.6	0
83	Prognostic and predictive effects of a gene expression signature for NRF2 pathway activation in lung squamous cell carcinoma (SqCC).. <i>Journal of Clinical Oncology</i> , 2013, 31, 7517-7517.	1.6	0
84	Feasibility of a randomized controlled trial of vitamin D vs. placebo in women with recently diagnosed breast cancer. <i>Breast Cancer Research and Treatment</i> , 2012, 134, 759-767.	2.5	16
85	Pharmacogenetic and Germline Prognostic Markers of Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2011, 6, 296-304.	1.1	35
86	Absolute benefits of medical therapies in phase III clinical trials for breast and colorectal cancer. <i>Annals of Oncology</i> , 2010, 21, 1411-1418.	1.2	28
87	<i>p53</i> Arg72Pro and <i>MDM2</i> T309G Polymorphisms, Histology, and Esophageal Cancer Prognosis. <i>Clinical Cancer Research</i> , 2009, 15, 3103-3109.	7.0	39
88	Discoloration of skin and urine after treatment with hydroxocobalamin for cyanide poisoning. <i>Cmaj</i> , 2009, 180, 251-251.	2.0	14
89	Presentation of Nonfinal Results of Randomized Controlled Trials at Major Oncology Meetings. <i>Journal of Clinical Oncology</i> , 2009, 27, 3938-3944.	1.6	28
90	Evolution of the Randomized Controlled Trial in Oncology Over Three Decades. <i>Journal of Clinical Oncology</i> , 2008, 26, 5458-5464.	1.6	136

#	ARTICLE	IF	CITATIONS
91	Barcoded Medication Administration. JAMA - Journal of the American Medical Association, 2008, 299, 2200.	7.4	19
92	Invasive Pulmonary Aspergillosis Associated With Marijuana Use in a Man With Colorectal Cancer. Journal of Clinical Oncology, 2008, 26, 2214-2215.	1.6	65
93	W4R variant in CSRP3 encoding muscle LIM protein in a patient with hypertrophic cardiomyopathy. Molecular Genetics and Metabolism, 2005, 84, 374-375.	1.1	21
94	CD2BP1 and CARD15 Mutations Are Not Associated with Pyoderma Gangrenosum in Patients with Inflammatory Bowel Disease. Journal of Investigative Dermatology, 2004, 122, 1054-1056.	0.7	15
95	Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nature Genetics, 2004, 36, 471-475.	21.4	749
96	Clinical Features and Short-term Outcomes of 144 Patients With SARS in the Greater Toronto Area. JAMA - Journal of the American Medical Association, 2003, 289, 2801.	7.4	1,188